TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06368960

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation： Hypofractionated radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation： Hypofractionated radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BM201 injection
Description: BM201 injection：Dose escalation：24mg to 240mg
Study: NCT06341972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy based self-management for anxiety
Description: Evidenced based approach for educating patients about how to manage anxiety after respiratory failure.
Study: NCT05315531

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water Intake
Description: Participants will increase plain water consumption to at least 70% of the daily adequate intake for Americans depending on their sex.
Study: NCT05515653

Intervention type: GENETIC
Intervention: Exposure to genetics (polygenic)
Description: The polygenic risk score (PRS) aggregates the effects of genetic variants into a single number that predicts the genetic predisposition to a phenotype. PRS are typically composed of hundreds to millions of genetic variants, usually Single Nucleotide Polymorphisms (SNPs). For each individual, the number of risk alleles computed in each variant is summed and weighted by the estimated value of the obtained effects (log odds ratio for traits with binary values or Beta coefficients for traits with continuous value) obtained from large-scale genomic studies ( GWAS)

Intervention type: GENETIC
Intervention: Exposure to genetics (polygenic)
Description: The polygenic risk score (PRS) aggregates the effects of genetic variants into a single number that predicts the genetic predisposition to a phenotype. PRS are typically composed of hundreds to millions of genetic variants, usually Single Nucleotide Polymorphisms (SNPs). For each individual, the number of risk alleles computed in each variant is summed and weighted by the estimated value of the obtained effects (log odds ratio for traits with binary values or Beta coefficients for traits with continuous value) obtained from large-scale genomic studies ( GWAS)
Study: NCT06000462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Mentioned in detailed description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Mentioned in detailed description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Mentioned in detailed description.
Study: NCT04592926

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham group will receive a pre-procedure sham scan (the handheld image guidance Accuro device will be placed on the back, but it will be turned off) followed by sham marking on the subject's back.
Study: NCT06459544

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bobath Technique with core stability
Description: exercise to improve balance motor learning stretegy is basically used. Bobath in which we assess patient's posture, inhibit the abnormal muscle tone and facilitate normal patterns and posture through handling and posture. we also use sensory inputs like propioception to promote normal pattern. we take some exercise based on bobath technique with core stability like Bridging with core stability, quadroped with core stability, sitting and standing with core stablity, single leg standing , dynamic balance with core stability.treatment plan based on 45 minutes per day, 6 days a week for 4 week.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional treatment for balance
Description: like stretching, strenthening the Lower extremity muscles , PROMS, AAROMS,AROMS, RROMS,some balance exercise like sitting and standing
Study: NCT04890457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation via tragus
Description: The device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation via tragus
Description: The device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation via earlobe
Description: The device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation via earlobe
Description: The device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
Study: NCT06397586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine volleyball
Description: MOtor imagery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine volleyball
Description: MOtor imagery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine volleyball
Description: MOtor imagery
Study: NCT05892445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic Warning Labels
Description: Based on a thorough review of the literature on e-cigarette risks and adverse effects, a graphic designer will be contracted to create ten experimental aversive health warnings related to e-cigarettes. These warnings will be exported as high-quality images and shown to participants in the intervention group prior to questions that obtain data on the primary endpoint.
Study: NCT05761236

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Sessions are consisted of scoliosis-specific pilates-based exercises.The exercises were kept constant in total content, but the bilateral or unilateral application directions, the number of repetitions for the right and left sides, and the extremities used were modified for each patient according to the localization of the major curve and the type of the curve. The taught postural corrections were requested to be maintained during all exercises. Exercises for flexibility were performed asymmetrically or symmetrically according to the chosen exercise, extremities were chosen according to the curve type, with 5 repetitions and 30 seconds for each repetition. Exercises aimed at strengthening were performed for a total of 12 repetitions, during a 5-second contraction, by arranging the number of repetitions for the right and left in line with the target muscles, again considering the curve type, and the patients were asked to rest between the exercises.
Study: NCT05012007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder Phone
Description: Standard reminder via phone (audiocare)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder Text
Description: reminder via text (VEText)
Study: NCT04918953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide atomization suspension
Description: (3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
Study: NCT05273021

Intervention type: DIAGNOSTIC_TEST
Intervention: TAPS
Description: all participants are investigated by the Dutch TAPS tool (Tobacco, Alcohol, Prescription medication and other Substances-tool). A screener and short assessment of possible substance use problems
Study: NCT05254405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone Injection [Zulresso]
Description: Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
Study: NCT05227599

Intervention type: OTHER
Group type: OTHER
Intervention: Online survey questionnaire
Description: Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms
Study: NCT05181202

Intervention type: OTHER
Intervention: Blood sampling
Description: Collect blood before drug injection. we do not intervene the clinical administration or drug choice or other clinical treatment.

Intervention type: OTHER
Intervention: Blood sampling
Description: Collect blood before drug injection. we do not intervene the clinical administration or drug choice or other clinical treatment.
Study: NCT04840563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kalifon A
Description: Commercially available kalifilcon A lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dailies Total1
Description: Dailies Total1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision1
Description: Precision1
Study: NCT06223776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
Study: NCT06391164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC243 25 mg
Description: Patients will receive the Investigated Product (IP) once in the morning at least 30 minutes before eating for 7-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC243 50 mg
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC243 75 mg
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
Study: NCT05378594

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge
Description: graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge
Description: graded nasal allergen challenge to increasing concentrations of allergen with monitoring of nasal symptoms and peak nasal inspiratory flow
Study: NCT05432661

Intervention type: DEVICE
Intervention: HİGH-FLOW NASAL OXYGEN USE (HFNO)
Description: It is aimed to show that the use of HFNO can improve oxygenation compared to the use of nasal cannula in ERCP procedures performed under sedation in the prone position.
Study: NCT06491810

Intervention type: OTHER
Intervention: Arm crank exercise
Description: The arm ergometer exercise will be the only intervention implemented during the study.
Study: NCT04798469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate 250 MG/ML
Description: Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration of placebo at baseline, weeks 4, and week 14.
Study: NCT05928832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up by a case-manager and access to the internet platform
Description: Patients in the intervention group receive an information letter on their discharge presenting the follow-up from which they benefit:call from the case-manager and access to the internet platform. The case-manager meets the patient and/or informal caregiver on the day of discharge from hospital. He recontacts the patient and/or informal caregiver within 7 days after returning home. A follow-up is offered to patients and caregivers following their return home, according to the objectives defined during the initial interview. The total duration of the support is 6 months maximum including at least 4 contacts with the case-manager,but this is refined and adapted with the patient, according to needs. Similarly, the frequency and methods (face-to-face or remote) of contact varies according to the needs of the patients and the stage of support, and is defined by the case-manager and patient. Patients and/or informal caregivers is also able to contact the case-manager 'on request'.
Study: NCT05411679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0057
Description: EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP0057
Description: EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablets
Description: Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor) Other names: Lynparza

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablets
Description: Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor) Other names: Lynparza
Study: NCT05415085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Culprit-first PCI
Description: PCI to the culprit artery prior to the demonstration of the whole coronary tree.
Study: NCT05789979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The resident-handling device
Description: Care staff will perform resident-handling tasks using the new resident-handling devices. For low dependency during trial, the device helps care staff to assist residents in making a transition from a sit to a standing posture, vice versa. This device is used for functional activities and transferring and lifting participants. For high dependency during trial, when care staff are performing resident-handling tasks, the device moves with little force in any direction.
Study: NCT06233864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: Disitamab Vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: Disitamab Vedotin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine
Study: NCT06380088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Task
Description: The exercise required participants to keep their arm flexed at a 90° angle while holding a dumbbell loaded to 80% of their 1RM (One Rep Max) in a supine position on the dominant side of the body for as long as possible.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Task
Description: The exercise required participants to keep their arm flexed at a 90° angle while holding a dumbbell loaded to 80% of their 1RM (One Rep Max) in a supine position on the dominant side of the body for as long as possible.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Task
Description: The exercise required participants to keep their arm flexed at a 90° angle while holding a dumbbell loaded to 80% of their 1RM (One Rep Max) in a supine position on the dominant side of the body for as long as possible.
Study: NCT06443840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutonHome® device
Description: The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.
Study: NCT05618964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Neck Flexors & Extensors exercises
Description: Deep neck flexor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck flexor muscle in supine Craniocervical flexion in supine~Deep Neck Extensor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck extensors in quadruped position Segmented extension movement with the head bent down onto their chest in a horizontal direction,
Study: NCT05793320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Release Surgery
Description: Carpal tunnel release surgery used to take a biopsy to diagnose amyloidosis and determine whether or not carpal tunnel syndrome can predict who's at risk for having amyloidosis.
Study: NCT05349474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 Mg Oral Tablet, up to 4 tablets a day
Description: Metformin 500 mg oral tablets to be titrated to 2000 mg/day divided over two doses or maximum tolerated dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet identical to metformin, up to 4 tablets a day
Description: Placebo tablets identical to metformin tablets. To be titrated to four tablets divded over two doses or maximum tolerated dose
Study: NCT05003154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digitalized management
Description: In addition to conventional management, Patients also receive digitalized management, which provides personalized guidance in diet, excercise, prenatal visit, blood glucose monitoring,etc., from artificail intelliegence (AI) supevised by obstetricians, through a smartphone application and some werable devices (like sports bracelet).~The pivotal AI are based on clinical experience from obstetricians, therapeutic principle from official Guidelines and abundant data in previous work, and it will works under strict supervision.
Study: NCT04780152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA). Anodal stimulation will be applied on F3 according to the intentional 10/20 system, and the cathode will be applied on the contra lateral position (F4).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-simulation of transcranial direct current stimulation
Description: Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine Tablets
Description: Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Tablets
Description: Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
Study: NCT05772338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNP105 (25 + 25 + 15)
Description: BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Up to six applications per day.
Study: NCT06508268

Intervention type: BEHAVIORAL
Intervention: GAITRite walkway system OR 4-meter walking speed test
Description: Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test

Intervention type: BEHAVIORAL
Intervention: GAITRite walkway system OR 4-meter walking speed test
Description: Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test

Intervention type: BEHAVIORAL
Intervention: GAITRite walkway system OR 4-meter walking speed test
Description: Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test

Intervention type: BEHAVIORAL
Intervention: GAITRite walkway system OR 4-meter walking speed test
Description: Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test

Intervention type: BEHAVIORAL
Intervention: Jamar hand dynamometer
Description: Hand grip strength will be assessed by a Jamar hand dynamometer
Study: NCT05296863

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil
Description: Non-concentrated ADSC-CM is given during week 0, 2, 4, and 6 on the left side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil
Description: Intervention is given during week 0, 2, 4, and 6 on the left side of the scalp. Minoxidil is applied twice using a spray, in the morning and at night.
Study: NCT06508268

Intervention type: BEHAVIORAL
Intervention: Jamar hand dynamometer
Description: Hand grip strength will be assessed by a Jamar hand dynamometer
Study: NCT05296863

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo and 5% Minoxidil
Description: Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo and 5% Minoxidil
Description: Intervention is given during week 0, 2, 4, and 6 on the right side of the scalp.~Minoxidil is applied twice using a spray, in the morning and at night.
Study: NCT04655001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORPH
Description: A 12-week movement and caloric restriction intervention meant to reduce pain and body weight.